Dr. Ramanathan is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
55 Lake Ave N
Worcester, MA 01655Phone+1 774-442-3903Fax+1 774-442-6715
Summary
- Dr. Muthalagu Ramanathan is an oncologist in Worcester, MA and is affiliated with UMass Memorial Medical Center. She received her medical degree from Kilpauk Medical College and has been in practice 20 years. She specializes in hematologic oncology and is experienced in hematopoietic stem cell transplantation, hodgkin's lymphoma, and transplantation conditioning. She has more than 40 publications and over 500 citings.
Education & Training
National Capital ConsortiumFellowship, Hematology and Medical Oncology, 2006 - 2009
Roger Williams Medical CenterResidency, Internal Medicine, 2002 - 2005
Kilpauk Medical CollegeClass of 1997
Certifications & Licensure
MA State Medical License 2009 - 2026
RI State Medical License 2004 - 2005- American Board of Internal Medicine Hematology
- American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- Meaningful Use Stage 1 Certification Centers for Medicare & Medicaid Services, 2011
Clinical Trials
- Lenalidomide With or Without Epoetin Alfa in Treating Patients With Myelodysplastic Syndrome and Anemia Start of enrollment: 2009 Jan 29
- Chronic Graft-versus-Host Disease Treatment (BMT CTN 0801) Start of enrollment: 2010 Apr 01
- Ibrutinib and Rituximab Compared With Fludarabine Phosphate, Cyclophosphamide, and Rituximab in Treating Patients With Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Start of enrollment: 2014 Feb 20
Publications & Presentations
PubMed
- Frameshift Mutations in Leukemia-Associated Genes Correlate With Superior Outcomes in Patients Undergoing Allogeneic Stem Cell Transplant forAcute Myeloid Leukemia.Emma Cammann, Sindha Madhav, Lloyd Hutchinson, Jan Cerny, Muthalagu Ramanathan
Journal of Hematology. 2024-06-01 - 1 citationsNatural history of clonal haematopoiesis seen in real-world haematology settings.Shyam A Patel, William K Gerber, Rena Zheng, Shrinkhala Khanna, Lloyd Hutchinson
British Journal of Haematology. 2024-05-01 - Midostaurin for FLT3-mutated AML: a real-world analysis of effectiveness and infection risk at a single center.Alice Kennedy, Shyam Patel, Muthalagu Ramanathan, Jonathan Gerber, Jan Cerny
Annals of Hematology. 2024-03-01
Journal Articles
- The incidence and impact of clostridioides difficile infection on transplant outcomes in acute leukemia and MDS after allogeneic hematopoietic cell transplant—a CIBMTR...Muthalagu Ramanathan et al, Bone marrow transplant, 12/21/2022
Lectures
- High Dose Mitoxantrone Based “5+1” Induction Chemotherapy Regimen in Newly Diagnosed Acute Myeloid Leukemia2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
- Hematopoeitic Cell Transplant - Comorbidity Index (HCT-CI) Score Is a Useful Tool for Predicting Induction Mortality and Overall Survival in Newly Diagnosed Acute Myel...2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Authored Content
- CDiff incidence and impact post allo sctDecember 2022
Press Mentions
Lupus Center at UMass Chan Investigates CAR T-cell Therapy for Severe or Unresponsive Lupus NephritisJuly 15th, 2024
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
